IGF-1 LR3
61,05 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
Description
IGF-1 LR3
Muscle / Growth / Recovery
MECHANISM OF ACTION
Long R3 IGF-1 analog: substitution of Arg at position 3 plus a 13-amino acid N-terminal extension. It minimizes affinity for IGF-binding proteins (IGFBP), drastically prolonging the half-life to 20–30 h compared to 12–15 min for native IGF-1. Full activation of the IGF-1 receptor: tyrosine kinase → MAPK, PI3K/Akt → protein synthesis, cell proliferation, and glucose uptake.
KEY BENEFITS
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
SIDE EFFECTS AND SAFETY
Risk of hypoglycemia; administer with food. Mandibular or organic growth at supraphysiological doses. Potential stimulation of the IGF-1 receptor pathway in an oncological context. Prohibited by WADA.
RESEARCH AND CLINICAL NOTES
Well-documented potency advantage over native IGF-1, with a half-life 10–100 times longer. Confirmed activation of muscle satellite cells. Ongoing clinical research on anti-aging.
TARGET PROFILE:
Advanced performance optimization programs, sarcopenia programs, and medically supervised injury recovery protocols.
Additional information
| Weight | ,26 kg |
|---|
Ingredients and Nutrition
Ingredient 1 - cucumber extract
Ingredient 2 - bilberry extract
Indications
1 capsule in the morning
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
New
KPV
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anti-inflammatory action in the intestines for IBD, Crohn's disease, and colitis.
- Restoration of intestinal barrier function in intestinal permeability protocols.
- Systemic anti-inflammatory effect without immunosuppression.
- Supports healing and reduces skin inflammation.
- Oral bioavailability for administration targeted at the gastrointestinal tract.
- Safe: extremely low molecular weight and no systemic toxicity.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Thymosin Alpha-1
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of T-cell immunity in immunocompromised patients.
- Reduction of viral load in hepatitis B and C.
- Adjunctive use in HIV, cancer immunotherapy, and sepsis.
- Improving the immune response to vaccines in older adults.
- Anti-inflammatory action through immune balance and Th1/Th2 regulation.
- Adjunctive use in COVID-19, with significant evidence from China and Italy.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
